Interleukin 10

Where the papers sit

11 papers from the last 6 months study interleukin 10 directly · updated from PubMed 16 Oct 2026

• Cytokine Immune Disease Research

  Cytokine profiling and immune signatures are being used to connect IL-10 and IL-6 with disease activity, prognosis and treatment opportunities. Plasma and cerebrospinal-fluid measurements address cancer and idiopathic intracranial hypertension, while melanoma signatures emphasize angiogenesis and immune regulation. Engineered IL-10-overexpressing MSCs and IL-10+VEGF-α+ neutrophils extend this work toward inflammatory bowel disease and neuroprotection. The evidence remains disease-specific rather than convergent.

  6 papers · 54.5%

• Targeted IL-10 Immunotherapy

  Cell-based and mRNA delivery strategies are moving IL-10 toward localized treatment of inflammation and tissue injury. Regulatory B cells target myeloid cells to reverse central nervous system autoimmunity. Pancreas-specific lipid nanoparticles alleviate acute pancreatitis, while cytokine-producing implants reduce foreign-body responses. Translation across rodents and nonhuman primates remains an important test.

  3 papers · 27.3%

• Phytochemical Mechanisms in Disease

  Network pharmacology and molecular docking are being used to predict how plant-derived compounds engage IL-10-linked inflammatory pathways. Panax notoginseng injection is being investigated for skin-wound repair, with fibroblast proliferation and Tnf among recurring mechanisms. Zanthoxylum nitidum phytochemicals are instead mapped to hepatocellular carcinoma targets. Experimental validation remains necessary to distinguish computationally plausible targets from therapeutic effects.

  2 papers · 18.2%